secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ventyx Biosciences, Inc. (—)
CIK:        0001851194
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001193125-26-090059
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eli Lilly completes acquisition of Ventyx Biosciences for $1.2B; $14.00 per share cash
--------------------------------------------------------------------------------

- Merger closed March 4, 2026; Ventyx becomes wholly owned subsidiary of Eli Lilly.
- Common stock converted to $14.00/share; preferred stock to $1,400/share; aggregate ~$1.2B.
- All prior directors and officers resigned; replaced by Eli Lilly appointees.
- Common stock delisted from Nasdaq; Form 25 filed; deregistration planned.
- Equity awards (options, RSUs) cancelled; holders receive cash based on $14.00/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851194/000119312526090059/0001193125-26-090059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851194/000119312526090059/d116049d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-090059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer